Market capitalization | $17.77m |
Enterprise Value | $46.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.63 |
P/S ratio (TTM) P/S ratio | 1.39 |
P/B ratio (TTM) P/B ratio | 0.37 |
Revenue growth (TTM) Revenue growth | -79.66% |
Revenue (TTM) Revenue | $12.75m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast ProPhase Labs, Inc.:
1 Analyst has issued a forecast ProPhase Labs, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 13 13 |
80%
80%
|
|
Gross Profit | -4.13 -4.13 |
114%
114%
|
|
EBITDA | -27 -27 |
187%
187%
|
EBIT (Operating Income) EBIT | -35 -35 |
131%
131%
|
Net Profit | -28 -28 |
165%
165%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer consumer healthcare products and dietary supplements. Its products include TK supplement. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Doylestown, PA.
Head office | United States |
CEO | Ted Karkus |
Employees | 113 |
Founded | 1989 |
Website | www.prophaselabs.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.